TG Therapeutics

Corporate Presentation

October 2020

Forward Looking Safe Harbor Statement

This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are often, but not always, made through the use of words or phrases such as "anticipates", "expects", "plans", "believes", "intends", and similar words or phrases. Such statements involve risks and uncertainties that could cause TG Therapeutics' actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks and uncertainties inherent in clinical trials, drug development, and commercialization and other risk factors identified from time to time in our reports filed with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and TG Therapeutics undertakes no obligation to update these statements, except as required by law.

Fearless Pursuit

- Founded 8 years ago with one goal in mind… to create the best possible treatment options for patients with B-Cell diseases

- Focused on cancer & autoimmune disease with registration programs ongoing in:
  - Chronic Lymphocytic Leukemia (CLL)
  - Marginal Zone Lymphoma (MZL)
  - Follicular Lymphoma (FL)
  - Multiple Sclerosis (MS)

146	4	5	35	5	1
EMPLOYEES	OFFICES	MEDICINES UNDER DEVELOPMENT	CLINICAL TRIALS	REGISTRATION-DIRECTED AND PHASE 3 CLINICAL TRIALS	GOAL: TO CURE B-CELL DISEASES

B-Cell Focused Platform
Clinical Stage Portfolio Overview

Drug Candidate	Mechanism of Action	Stage of Development
Umbralisib (TGR-1202)	PI3Kδ/CK1ε	Phase 3
Ublituximab (TG-1101)	Anti-CD20	Phase 3
Cosibelimab (TG-1501)	Anti-PD-L1	Phase 1b
TG-1701	BTKi	Phase 1
TG-1801	Anti-CD47/CD19	Phase 1

2020: Transformational Year w/ Multiple Pivotal Data Sets

UNITY-NHL Rel/Ref MZL and FL	UNITY-CLL Front Line & Rel/Ref	ULTIMATE I & II Relapsing MS
– Umbralisib Monotherapy –	*– Umbralisib + Ublituximab (U2) –*	*– Ublituximab Monotherapy –*
Positive Topline ORR Data	Trial Conduced Under SPA	Trials Conducted under SPA
ODD Granted for MZL & FL and BTD granted for MZL	Enrolled ~420 patients	Enrolled Over 1100 Patients
Rolling NDA Submission accepted by the US FDA August 2020	**Positive topline results announced May 2020**	**Awaiting topline results, Target 4Q 2020**

- *Potential for FDA Approvals in MZL, FL, CLL, SLL and MS from 2020 to 2022*
- *Commercial Preparations Underway*

Umbralisib:

Investigational dual PI3k-delta & CK1-epsilon inhibitor

- *Demonstrated activity across NHL and CLL*
- *Potentially differentiated tolerability profile over 1st generation compounds*
- *Once daily v. twice daily for 1st generation compounds*

UNITY-NHL - *Umbralisib Monotherapy Cohorts*

Relapsed/Refractory MZL & FL

- MZL & FL Cohort's Met Primary End Point of Overall Response Rate (ORR)
  - Exceeding 40% ORR hurdle
  - Interim efficacy analysis of MZL cohort, n=42, showed 52% ORR, including 19% Complete Response (CR) rate
- Umbralisib monotherapy appeared to be well tolerated in both cohorts, with a safety profile consistent with previous reports
- **Rolling NDA submission for umbralisib to treat R/R MZL and FL accepted by the US FDA August 2020**
  - MZL PDUFA goal date of February 15, 2021
  - FL PDUFA goal date of June 15, 2021
- **Targeting presentation of full data by year-end 2020**

UNITY-NHL Ph2b Trial
FL & MZL Cohorts

Umbralisib (TGR-1202) Monotherapy

Positive Topline ORR Results	
Target ORR Achieved	>40%
Enrollment Complete	
MZL (n=69)	Aug 2018
FL (n=118)	Oct 2018
Targeting Full Data Presentation	YE 2020

MZL and FL are chronic and often incurable diseases characterized by multiple recurrences and relapses[1]

Marginal Zone and Follicular Lymphomas
Estimated # of Annually Treated Patients in US[2]

1L 18,000 – 20,000[a]

1L TREATMENT:
Primarily CD20-based chemo[3]

2L ~7,000[b]

2L TREATMENT:
Variable with ~50% CD20-based chemo [3]

3L+ ~3,500[c]

3L+ TREATMENT:
No standard of care:
PI3Ki and unapproved therapies[3]

~10,000-11,000 treated relapsed/refractory MZL or FL patients in the US

Response and remission duration decline with subsequent treatments, and cumulative toxicities increase[3,4]

Continued need for active, well-tolerated treatment options for R/R MZL & FL

a=FL: 12,000 treated; MZL: 6,000 treated; b= FL: 5,000 treated, MZL: 2,500 treated; c=FL: 2,500 treated, MZL: 1,000 treated. (expect FDA approval in 2L+ MZL and 3L+FL)

(1) Denlinger NM, et al. *Cancer Manage Res* 2018; Rivas-Delgado A, et al. *Brit J Haematology* 2019; (2) Putnam Associates, 2018; (3) Putnam Associates, 2019; (4) Kritharis A, et al. *Cancer Treatment and Research,* 2015; 5. Morrison V, et al. *Clin Lymphoma, Myeloma, and Leukemia*. 2019]

Ublituximab:

Investigational Next Generation Anti-CD20 Monoclonal Antibody



US REGULATORY SUBMISSION PLAN TARGETS

CLL ***(in combo with umbralisib)***	***YE* 2020/ early 2021**
Multiple Sclerosis	**1H 2021**

Ublituximab
Glycoengineered for enhanced potency over 1st generation
Activity in rituximab refractory patients
Shorter infusion time than approved anti-CD20s

UNITY-CLL Phase 3 Trial of U2 in CLL

POSITIVE TOPLINE RESULTS – MAY 2020

- **UNITY-CLL met the primary endpoint of improved PFS (p<.0001)**
- Trial will be stopped early for superior efficacy observed at the interim analysis
- PFS benefit seen across both treatment naïve & relapsed/refractory patient populations
- **Full data presentation and regulatory submission targeted by year-end 2020/early 2021**



Enrollment	~420
Primary Endpoint	PFS
Met Primary PFS Endpoint	May 2020
Patient Population	1L/2L+

Conducted under Special Protocol Assessment

Barr et al., ASH 2019; Burris et al., 2018; Mato A, et. al, Lugano 2019; Lunning et al., 2019

CLL Market Opportunity

One of the Fastest Growing Global Hematology Markets

- **~115,000 Americans living with CLL**
- **~20,000 newly-diagnosed patients each year**
- **~20,000 previously treated patients seeking treatment each year**



*Evaluate Pharma

U2 Has the Potential to Address Unmet Needs in CLL

- **Over 60,000 patients** in the US have been treated with a BTK-inhibitor creating a large population in the post-BTK setting in need of treatment options
- **~20% of treatment naïve patients will be deemed poor candidates** for BTK inhibitors due to potential safety/tolerability concerns
- **Up to 40% of patients will discontinue** BTK inhibitors for efficacy/tolerability issues at median of 17 months from starting therapy in recent real-world analysis
- **Venetoclax represents a challenge for community practices** due to enhanced monitoring and potential need for hospitalization to avoid TLS

➢ ***Substantial need for additional treatments for CLL remains***

TG Internal Research; Mato et al., 2018

U2-Based Triplets Currently Enrolling

U2 + Venetoclax

ULTRA-V
U2-V IN CLL

Target Enrollment:	
Rel/Ref CLL	~60 patients
BTK Refractory CLL	~30 patients
Front line CLL	~60 patients
Completion	Q1 2021
Primary Endpoint(s):	ORR and CR @ 12 months
Phase 1 U2+Ven ASH '19 Update *(Barr et al)*	CLL Patients: ORR= 100% (n=9) CR= 44% PB MRD-= 100% BM MRD-= 78%

U2 + Ibrutinib

Phase 1 Study in rel/ref B-cell malignances

Enrolled:	~50 patients
Published:	Lancet Oncology, Jan. 2019
Primary Endpoint(s)	Safety, Efficacy
Lancet Jan 2019 (Nastoupil et al)	CLL/SLL Patients: ORR= 100% (n=22) CR= 36% (8/22) MZL Patients: ORR= 100% (3/3)

U2 + 1701 (BTKi)

Phase 1 Study in rel/ref B-cell malignances

Target Enrollment:	Up to 100 patients
Target Determination of Ph 3 Dose:	Q4 2020
Primary Endpoint(s)	Safety
EHA '20 Update (Cheah et al)	Triple U2 +1701: All Patients ORR= 77% (n=13) CLL ORR= 100% (3/3) MZL ORR= 100% (2/2) Single Agent 200mg: CLL ORR= 92% (11/12)

Ublituximab in Relapsing Forms of Multiple Sclerosis

- ~1M Americans living with MS
- Completed Phase 2, data presented at multiple conferences
- Fully Enrolled Phase 3 ULTIMATE Trials
  - Special Protocol Assessment (SPA)
    - **Topline Data Targeted for Q4 2020**



Final Ublituximab Phase 2 Data in RMS

- Ublituximab was well tolerated across all patients (n=48)
- No study drug related discontinuations occurred
- Median B cell depletion was >99% at the primary analysis point of Week 4 (n=48) and maintained at Week 24 and Week 48
- No T1 Gd-enhancing lesions were detected in any subjects at Week 24 or Week 48 (100% reduction; p=0.003)
- **An Annualized Relapse Rate (ARR) of 0.07 was observed with 93% of subjects relapse free at Week 48**





This is one study participant's MRI; individual results vary.

Fox E et al., ECTRIMS 2018

Significant Opportunity for Ublituximab in MS

Global MS Market 2018 - 2025



Global Prevalence = ~2.3Million

Global Market Size >$30Billion by 2025

- **Ocrelizumab >$2 Billion in 2018 annual sales; achieved ~$4B in 2019**

Source: Datamonitor 2018 MS Report; Prevalence Estimate: Nat'l MS Society; Roche JPM 2018 Corporate Update

Multiple Treatment Options Coexist & Account for Meaningful Market Share

Class	Drug	U.S. Approval Date	Route of Administration	Dosing	Global 2018 Revenues by Drug/Class ($ in millions)
Interferons	Betaseron	1993	Subcutaneously	1x / 2 days	$643
	Avonex (interferón beta-1a)	1996	Intramuscularly	1x / week	$1,915
	Rebif	2002	Subcutaneously	3x / week	$1,732
	Extavia	2009	Subcutaneously	1x / 2 days	$162
	plegridy (peginterferon beta-1a)	2014	Subcutaneously	1x / 2 weeks	$448
IV Potent Immunomodulators	Tysabri (natalizumab)	2004	Intravenously	1x / 4 weeks	$1,864
	Lemtrada (alemtuzumab)	2014	Intravenously	3x / year	$475
T-Cell Targeted Orals	Gilenya (fingolimod)	2010	Orally	1x / day	$3,380
	Aubagio (teriflunomide)	2012	Orally	1x / day	$1,945
	Tecfidera (dimethyl fumarate)	2013	Orally	2x / day	$4,274
CD20s	Ocrevus (ocrelizumab)	2017	Intravenously	2x / year	$2,406 * Now >$4B+
	Ofatumumab	2020	Subcutaneously	1x / 4 weeks	TBD
	Ublituximab	2021	Intravenously	2x / year	TBD

Source: Evaluate Pharma, Wall Street Research

Ublituximab Potential Value Proposition in MS

- Significant activity and manageable safety profile in Phase 2 study
- Convenience of 1 hour infusion every 6 months v. 3-4 hours for ocrelizumab
- Potential to strategically price to optimize patient access
- ***Estimate $1-2B annual market opportunity in the US alone for ublituximab in MS***

Target Milestones

1H 2020

- Report topline UNITY-NHL FL results
- Initiate rolling NDA submission for umbralisib to treat relapsed/refractory MZL & FL
- Report topline UNITY-CLL results
- Present updated data at major medical meetings
- Complete NDA submission for umbralisib to treat relapsed/refractory MZL & FL

2H 2020 – Q1 2021

- NDA submission for umbralisib to treat MZL & FL accepted by US FDA & PDUFA goal dates set
- Report topline Phase 3 ULTIMATE MS data
- Present final data from UNITY-CLL & UNITY-NHL umbralisib monotherapy MZL & FL cohorts
- Submit NDA/BLA for U2 to treat CLL
- Complete enrollment in ULTRA-V Phase 2b trial

Corporate & Financial

Key Financial Statistics

Ticker:	TGTX (NASDAQ)
Price:	$27.56 (close on 10/5/2020)
Shares:	~127M (fully-diluted as of 6/30/20)
Cash:	$275M (as of 6/30/20)

TG Therapeutics

NASDAQ: TGTX